USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $0.00 | $-0.22 | $-0.18 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Nov 3, 2021 | Sep 2021 | $250.00K | $700.00K | $0.00 |
Bellicum Pharmaceuticals, Inc's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 0 | $0.00 | $0.00 | $0.00 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 0 | $0.00 | $0.00 | $0.00 |
| Dec 2022 | 0 | $0.00 | $0.00 | $0.00 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-0.92 | $-0.92 | $-0.92 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 0 | $-5.03 | $-5.03 | $-5.03 |
| Dec 2022 | 0 / 0 | $-2.93 | $-2.93 | $-2.93 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $250.00K | $250.00K | $250.00K |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 1 | $0.00 | $0.00 | $0.00 |
| Dec 2022 | 1 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 12, 2021 | Jun 2021 | $-0.85 | $-0.22 | 74.12% |
| May 14, 2021 | Mar 2021 | $-1.37 | $-1.12 | 18.25% |
| Mar 30, 2021 | Dec 2020 | $-1.06 | $0.98 | 192.45% |
| Nov 5, 2020 | Sep 2020 | $-3.15 | $-0.18 | 94.28% |
| Aug 6, 2020 | Jun 2020 | $-2.87 | $-8.55 | -197.91% |
| May 7, 2020 | Mar 2020 | $-2.73 | $1.09 | 139.93% |
| Mar 12, 2020 | Dec 2019 | $-4.34 | $-5.82 | -34.26% |
| Nov 6, 2019 | Sep 2019 | $-5.30 | $-6.80 | -28.30% |
| Aug 5, 2019 | Jun 2019 | $-5.40 | $-5.80 | -7.41% |
| May 7, 2019 | Mar 2019 | $-5.82 | $-5.50 | 5.50% |
| Mar 12, 2019 | Dec 2018 | $-6.46 | $-6.30 | 2.48% |
| Nov 6, 2018 | Sep 2018 | $-5.68 | $-5.50 | 3.08% |
| Aug 7, 2018 | Jun 2018 | $-5.63 | $-6.00 | -6.67% |
| May 8, 2018 | Mar 2018 | $-7.04 | $-6.80 | 3.45% |
| Mar 13, 2018 | Dec 2017 | $-6.97 | $-6.60 | 5.33% |
| Nov 7, 2017 | Sep 2017 | $-7.40 | $-7.10 | 4.05% |
| Aug 8, 2017 | Jun 2017 | $-6.63 | $-7.40 | -11.64% |
| May 8, 2017 | Mar 2017 | $-7.04 | $-8.00 | -13.68% |
| Mar 13, 2017 | Dec 2016 | $-7.33 | $-7.40 | -0.97% |
| Nov 9, 2016 | Sep 2016 | $-6.34 | $-6.60 | -4.10% |
| Aug 8, 2016 | Jun 2016 | $-5.80 | $-6.10 | -5.17% |
| May 9, 2016 | Mar 2016 | $-5.10 | $-5.60 | -9.80% |
| Mar 14, 2016 | Dec 2015 | $-4.20 | $-6.30 | -50.00% |
| Nov 9, 2015 | Sep 2015 | $-0.38 | $-0.51 | -34.21% |
| Aug 13, 2015 | Jun 2015 | $-0.49 | $-0.40 | 18.37% |
| May 11, 2015 | Mar 2015 | $-0.30 | $-0.30 | - |
| Mar 11, 2015 | Dec 2014 | $-0.37 | $-2.02 | -445.95% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 30, 2021 | Dec 2020 | $-8.70 | $-6.66 | - |
| Mar 12, 2020 | Dec 2019 | $-22.17 | $-23.92 | - |
| Mar 12, 2019 | Dec 2018 | $-2.37 | $-24.60 | - |
| Mar 13, 2018 | Dec 2017 | $-2.94 | $-29.10 | - |
| Mar 13, 2017 | Dec 2016 | - | $-25.70 | - |
| Mar 14, 2016 | Dec 2015 | - | $-7.51 | - |
| Mar 11, 2015 | Dec 2014 | - | $-2.02 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 12, 2021 | Jun 2021 | $250.00K | $700.00K | 2.80% |
| May 14, 2021 | Mar 2021 | $250.00K | $0.00 | - |
| Mar 30, 2021 | Dec 2020 | $250.00K | $0.00 | - |
| Nov 5, 2020 | Sep 2020 | $250.00K | $0.00 | - |
| Aug 6, 2020 | Jun 2020 | $900.00K | $0.00 | - |
| May 7, 2020 | Mar 2020 | $400.00K | $5.13M | 12.83% |
| Mar 12, 2020 | Dec 2019 | $630.00K | $5.13M | 8.15% |
| Nov 6, 2019 | Sep 2019 | $1.20M | $103.00K | 0.09% |
| Aug 5, 2019 | Jun 2019 | $750.00K | $1.39M | 1.85% |
| May 7, 2019 | Mar 2019 | $650.00K | $516.00K | 0.79% |
| Mar 12, 2019 | Dec 2018 | $1.19M | $312.00K | 0.26% |
| Nov 6, 2018 | Sep 2018 | $110.00K | $292.00K | 2.65% |
| Aug 7, 2018 | Jun 2018 | $70.00K | $362.00K | 5.17% |
| May 8, 2018 | Mar 2018 | $30.00K | $154.00K | 5.13% |
| Mar 13, 2018 | Dec 2017 | $980.00K | $-69.00K | - |
| Nov 7, 2017 | Sep 2017 | $30.00K | $126.00K | 4.20% |
| Aug 8, 2017 | Jun 2017 | $80.00K | $128.00K | 1.60% |
| May 8, 2017 | Mar 2017 | - | $128.00K | - |
| Mar 13, 2017 | Dec 2016 | - | $81.00K | - |
| Nov 9, 2016 | Sep 2016 | - | $114.00K | - |
| Aug 8, 2016 | Jun 2016 | - | $101.00K | - |
| May 9, 2016 | Mar 2016 | - | $92.00K | - |
| Mar 14, 2016 | Dec 2015 | - | $34.00K | - |
| Nov 9, 2015 | Sep 2015 | - | $57.00K | - |
| Aug 13, 2015 | Jun 2015 | - | $84.00K | - |
| May 11, 2015 | Mar 2015 | - | $107.00K | - |
| Mar 11, 2015 | Dec 2014 | - | $15.00K | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 30, 2021 | Dec 2020 | $0.00 | $500.00 | - |
| Mar 12, 2020 | Dec 2019 | $2.48M | $7.14M | 188.02% |
| Mar 12, 2019 | Dec 2018 | $1.97M | $1.12M | -43.15% |
| Mar 13, 2018 | Dec 2017 | $1.12M | $185.00K | -83.48% |
| Mar 13, 2017 | Dec 2016 | - | $388.00K | - |
| Mar 14, 2016 | Dec 2015 | - | $282.00K | - |
| Mar 11, 2015 | Dec 2014 | - | $1.78M | - |
BLCM's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.
According to 0 analysts, the average EPS estimation for Bellicum Pharmaceuticals, Inc's next quarterly earnings is $0.00, with a low EPS estimation of $0.00, and a high estimation of $0.00.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-1.37, the last 2 month trend is $-1.37, and the 3 month trend is $-1.37.
Based on 1 analysts, the average revenue estimation is $250.00K, with a low revenue estimation of $250.00K, and a high estimation of $250.00K.
Bellicum Pharmaceuticals, Inc's previous earnings date was Aug 12, 2021 for its fiscal quarter ended Jun 30, 2021.
BLCM's earnings per share (EPS) was $-0.22, beating the consensus analysts forecast of $-0.85 by 74.12%.
The EPS was higher than the previous fiscal quarter (Mar 2021) by -80.36%, and higher than the same period a year before (Jun 2020) by -97.43%.
Revenues were $700.00K.
The company reported a net income of $-2.20M.Free cash flow for the quarter was $-7.79M , compared to $-8.29M last quarter and $-14.41M a year before.
BLCM ended the quarter with $39.00K in total debt, a decrease of -32.76% compared to the previous quarter, and a decrease of -99.86% compared to the same quarter a year before.
Bellicum Pharmaceuticals, Inc's previous annual earnings date was Mar 30, 2021 for its fiscal year ended Dec 31, 2020.
BLCM's earnings per share (EPS) was $-6.66, beating the consensus analysts forecast of $-8.70 by -23.45% , and higher than the previous year's EPS (Dec 2019) by -72.16%.
Revenues were $500.00.
The company reported a net income of $-7.72K.
Bellicum Pharmaceuticals, Inc reported a free cash flow of $-55.38M for its fiscal year, compared to $-78.09M a year ago.
The company ended the fiscal year with $825.00K in total debt, a decrease of -97.78% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.